IVIEW Therapeutics Announces First-in-Human Dosing of IVW-1001, a Novel TRPM8 Agonist for Dry Eye Disease, in Phase I/II Clinical Trial
iView Therapeutics
Ophthalmic Innovative Drug Developer
Proxima Venture · Report
[June 25, 2024, Cranbury, New Jersey, USA] --- iView Therapeutics Inc. --- a clinical-stage biotechnology company dedicated to the development of innovative ophthalmic drugs, today announced that the companyNovel Compound of Class I Innovative DrugIVW-1001Clinical Trials for the Treatment of Dry Eye SyndromeIn Indianapolis, USAProceedFirst Subject Dosed. This milestone marks the beginning of the clinical evaluation trial for IVW-1001. IVW-1001 is a novel TRPM8 cold receptor agonist designed to treat the signs and symptoms of dry eye disease.
The initiation of dosing in the Phase I/II clinical trial marks a significant advancement in iView Therapeutics' mission to develop innovative solutions for patients with dry eye disease, particularly for those whose condition does not improve with artificial tears. ThisFirst-in-Human (FIH) Clinical TrialConducted across more than ten clinical centers in the United States, aimed at rigorously evaluating IVW-1001Safety, Tolerability, and Efficacy。
Dry eye syndrome is a common and complex ophthalmic disease., affecting millions of people worldwide. IVW-1001, a novel compound and innovative drug developed by iView Therapeutics, offers promising therapeutic potential by targeting the underlying causes of dry eye disease through the mechanism of TRPM8 cold receptor agonists. ThroughEyelid WipingThe innovative drug delivery route further demonstrates IVW-1001 as a potentialDifferentiated Breakthrough TherapyFeatures.
Ophthalmologist Houman Hemmati, M.D.——Chief Medical Advisor Leading the Clinical Development of IVW-1001 ProjectSaid: "In our Phase I/II clinical trial, dosing the first patient subject is an exciting and crucial step. Our focus remains on comprehensively evaluating the safety and potential efficacy of IVW-1001. This TRPM8 agonist under investigation offers an innovative approach to treating dry eye disease, and we are committed to advancing this program to address unmet clinical needs for patients worldwide."
Dr. Bo Liang, MBA, Co-founder, Chairman and CEO of iView Therapeutics, Inc."We are delighted to initiate the clinical study of IVW-1001 and commence dosing in the first subject. This milestone underscores our pioneering commitment to treating dry eye disease and highlights the potential of our novel TRPM8 activation mechanism for dry eye treatment. We look forward to the progress of this trial and the new insights it will provide into the treatment of dry eye disease."
About • iView Therapeutics
IVIEW Therapeutics Inc.
IVIEW Therapeutics is a clinical-stage ophthalmic innovative drug development company. iView Therapeutics (Zhuhai Hengqin) Co., Ltd. is the wholly-owned subsidiary of IVIEW Therapeutics Inc. in China. The company is committed to developing clinically differentiated products to address unmet clinical needs. Focusing on innovative science, novel mechanisms of action, and differentiated drug delivery technology platforms, the company develops a pipeline of products with potential commercial differentiation advantages. Its innovative portfolio of small molecules and gene therapy products covers first-in-class and second-class innovative drugs for infectious conjunctivitis, dry eye syndrome, myopia, presbyopia, glaucoma, and more. Headquartered in Cranbury, New Jersey, in the Princeton area, IVIEW Therapeutics occupies 11,045 square feet of laboratory and office space. iView Therapeutics (Zhuhai Hengqin) Co., Ltd. is located in the Traditional Chinese Medicine Industrial Park of the Guangdong-Macao In-Depth Cooperation Zone in Hengqin, Zhuhai, Guangdong Province.
